The Jackson Laboratory receives an up to $30 million contract award to revolutionize drug safety testing with AI-powered "virtual hearts"

New CARDIOVERSE project combines AI, stem cells, and genetic variation to predict drug safety before human trials

BAR HARBOR, Maine, Dec. 8, 2025 /PRNewswire/ -- Developing new drugs is one of the riskiest and most expensive endeavors in science. Today, The Jackson Laboratory (JAX) announced a bold initiative to improve that trajectory, powered by an up to $30 million contract from the Advanced Research Projects Agency for Health (ARPA-H) Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program. CATALYST is led by ARPA-H Health Science Futures Mission Office Acting Deputy Director Andy Kilianski, Ph.D.